BMS bids $4.5B for ImClone

They're partners on the cancer med Erbitux, so why not join forces completely? Bristol-Myers Squibb has offered $4.5 billion for ImClone Systems, a $60-per-share price that represents about a 40 percent premium over the past month's closing prices. Release | Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.